Outstanding. I now have everything needed from primary sources — CMS, KFF, Health Affairs, Clarivate, AAF, Pharmaphorum, Epstein Becker Green. Let me write the fully corrected, publication-ready version now.
By Frank F. Dolan, CEO, Arsenal Advisors
- The first cycle’s 10 negotiated prices took effect January 1, 2026; CMS estimated those prices would have cut 2023 net Medicare spending by $6 billion — a 22% reduction — if they had been in effect then. The published MFPs were 38%–79% below list prices.
- American Action Forum
- The program is already past round one: CMS finalized negotiated prices for 15 additional Part D drugs for 2027, with estimated savings of $8.5 billion in net covered drug costs
- , and on January 27, 2026, CMS announced 15 drugs payable under Medicare Part B and/or covered under Medicare Part D selected for the third cycle of negotiations, plus one drug selected for the first-ever renegotiation
- The IRA’s commercial impact is not only price compression: in 2026, the Part D redesign also brought a $2,100 annual out-of-pocket threshold, mandatory formulary inclusion of selected drugs, and a selected-drug subsidy that lowers Part D sponsor liability on negotiated prices
- This is the first year CMS is required to negotiate physician-administered drugs covered under Medicare Part B
- — meaning the program has crossed from retail pharmacy into buy-and-bill territory, with implications for an entirely different set of commercial organizations
The Program Is Not Coming. It Is Here, and It Is Scaling.
For years, pharmaceutical commercial leaders treated the Inflation Reduction Act as a policy development to monitor — something to hand to the government affairs team while the commercial organization focused on launch execution and field force optimization.
That posture was always a mistake. As of January 1, 2026, it is an operational liability.
The first ten drugs selected under the IRA’s Medicare Drug Price Negotiation Program are now operating under Maximum Fair Prices set by the Centers for Medicare and Medicaid Services. In all ten negotiations, CMS obtained reductions greater than the mandatory minimums required under the IRA. Only one of 30 insurance company executives surveyed by Clarivate in early 2024 expected CMS to obtain a cut larger than the mandatory minimum for all 10 drugs. Clarivate CMS exceeded the mandatory minimum on every single one.
And the program is not standing still. The second cycle is complete — 15 additional Part D drugs with negotiated prices taking effect January 1, 2027. On March 13, 2026, CMS announced that all 15 manufacturers selected for the third cycle have chosen to participate in negotiations, along with the manufacturer of the one drug selected for the program’s first renegotiation. CMS This is a three-cycle-and-growing program, not a one-time experiment.
What the Numbers Actually Say
Getting the financial scope right matters for commercial planning, so it is worth being precise about what CMS’s own estimates show.
For the first cycle, CMS estimated that if the MFPs had been in effect in 2023, Medicare would have saved $6 billion in net covered prescription drug costs — representing 22% lower net spending across those drugs. American Action Forum That is the net-price story, distinct from the 38%–79% headline figure, which represents reductions against list prices. Sophisticated payers, commercial analytics teams, and any investor modeling this impact need to keep those two numbers separate.
For the second cycle, CMS estimates show $8.5 billion in net savings, representing a 36% reduction, when the Coverage Gap Discount Program spending is included — or $12 billion (44%) under a different net savings convention. American Action Forum The second-cycle discounts are deeper on average, in part because the 2027 cohort includes high-spend GLP-1s and oncology agents with more room between list prices and MFPs.
The third-cycle cohort — the 15 drugs selected in January 2026 for 2028 effective dates — accounted for about $27 billion in prescription drug spending on Medicare between November 2024 and October 2025. Fierce Pharma Applying the CMS-anchored savings rates from cycles one and two suggests the third cycle will deliver meaningful additional net savings when negotiations conclude later this year.
McKinsey’s broader structural analysis puts the industry-wide financial pressure in context: the IRA is projected to reduce pharma EBITDA by $50 to $70 billion through 2028. That is not a rounding error. It is a structural shift in the economics of the industry that forces explicit choices about where commercial resources are deployed.
The Part D Redesign: The Commercial Story Most Teams Are Missing
The IRA’s commercial impact in 2026 is not only about Maximum Fair Prices. A parallel set of changes to the Part D benefit structure took effect January 1 that are reshaping payer economics and formulary behavior — and, by extension, every manufacturer’s commercial strategy.
Three changes matter most for commercial teams.
First, the annual beneficiary out-of-pocket cap. The $2,000 cap introduced in 2025 has been increased to $2,100 for 2026, indexed to average Part D cost growth. Mintz For patients on high-cost therapies, this cap reduces the financial barrier to adherence — but it also changes the math on how plans manage utilization and formulary placement for expensive drugs.
Second, mandatory formulary inclusion. Consistent with the IRA’s coverage requirement, in 2026, all Part D enrollees have coverage of all 10 selected drugs with negotiated prices, including all dosage forms and strengths. Moreover, access to several doses and forms of 9 of the first 10 drugs selected for negotiation has improved since 2025. KFF For those brands, this is a coverage improvement. For their competitors, it raises the bar for formulary positioning and reinforces the pressure to match or beat the MFP on net price.
Third, the selected drug subsidy. The IRA’s redesign of Part D includes a 10% government subsidy to reduce Part D plan liability for selected drugs. Mintz This subsidy changes sponsor economics in ways that affect how plans bid, how they position selected drugs relative to alternatives, and what the net revenue flow looks like for manufacturers — considerations that should be embedded in gross-to-net planning for any brand operating in a therapeutic category where a selected drug competes.
The commercial leader who is thinking only about MFPs is missing half the picture.
The Ripple Effect: Payers Are Signaling Broader Market Repricing
The IRA’s price impact is not limited to the drugs currently in negotiation. Clarivate’s survey found that across all therapeutic areas, a majority of payers expected the competitors of negotiated drugs to match or beat the reduced net price if they seek to retain their current coverage and management. Payers also said they are likely to penalize drugs that do not adjust their price sufficiently via downgraded coverage, including the imposition of step therapy. Clarivate
This is payer expectation data from 2024, not yet a documented broad market repricing event. The first IRA prices only hit pharmacy counters on January 1, 2026, so it is too early to observe the full downstream commercial market impact. But the direction of travel is clear, and the formulary levers are real.
When asked how the impact of reduced Medicare prices would affect commercial net prices, none of the payers surveyed by Clarivate expected commercial net prices to remain the same. Two-thirds expected commercial net prices to fall. One-third expected them to rise — reasoning that manufacturers would compensate for Medicare revenue loss by reducing commercial rebates. Clarivate
Either scenario — falling net prices or reduced commercial rebates — changes the gross-to-net dynamics for affected brands. The commercial organization still modeling pre-IRA economics is building on a foundation that no longer exists.
The Pill Penalty: The Timeline Problem Commercial Leaders Are Underplanning For
Buried inside the IRA’s negotiation framework is a structural asymmetry that receives far less attention in commercial circles than it deserves.
Small-molecule drugs become eligible for selection 7 years after FDA approval, with negotiated prices taking effect approximately 2 years later — meaning the practical commercial countdown to an MFP is roughly 9 years from approval. Biologics become eligible for selection 11 years after licensure, with prices effective approximately 2 years after that — a roughly 13-year commercial runway. The industry has called the 4-year gap the “pill penalty,” and it is already reshaping R&D strategy and portfolio prioritization at the earliest stages of pipeline planning.
For commercial leaders, the implication is direct: launch plans for small-molecule drugs need to account for a negotiation-eligible window that arrives faster than it does for biologic competitors. The 5-year commercial plan that doesn’t model IRA negotiation risk for a small molecule approaching year 7 is incomplete.
There is one significant recent development that cuts the other way. The 2025 reconciliation law broadened the orphan drug exclusion from negotiation in two ways: making orphan drugs designated for multiple rare diseases ineligible for negotiation (not just a single rare disease), and delaying the start of the 7- or 11-year selection clock for orphan drugs that subsequently receive FDA approval for a non-orphan indication. These changes likely had an impact on which drugs were selected for the 2028 cycle by delaying the selection of Keytruda and Opdivo. KFF The CBO estimated this change will increase Medicare spending by at least $5 billion over the coming decade.
For portfolio strategists and commercial planners, the broadened orphan exclusion is meaningful: it creates additional runway for drugs that qualify, changes the competitive dynamics in rare disease categories, and signals that the legislative architecture around IRA negotiation continues to evolve.
Part B: The Expansion That Changes Everything for Specialty Pharma
The third negotiation cycle marks a fundamental expansion of the program’s scope. CMS has announced the selection of 15 high-cost prescription drugs for the third cycle — and for the first time, drugs payable under Medicare Part B are included. CMS
This is a structural change, not a marginal one. Part D covers retail, pharmacy-dispensed prescription drugs. Part B covers physician-administered drugs — infused biologics, injectable oncologics, chemotherapy agents administered in clinics and hospital outpatient settings. The commercial model for Part B drugs operates on entirely different economics: buy-and-bill reimbursement, J-code billing, average sales price (ASP)-based pricing, and hospital formulary committee dynamics rather than PBM contracting.
AbbVie’s Botox — selected for the third cycle — illustrates the stakes. In 2025, Botox’s therapeutic indications generated almost $3.77 billion worldwide in sales. AbbVie filed a new lawsuit in February 2026 challenging Botox’s inclusion, arguing that it qualifies for the IRA’s plasma-derived product exclusion. Fierce Pharma
The expansion into Part B means that any organization with a physician-administered drug in a high-spend Medicare category needs to treat IRA negotiation risk as a first-order commercial planning variable — not a policy monitor item.
The Litigation Landscape: Implementation Default, Not Wait-and-See
In the years immediately following the IRA’s passage, a number of pharma companies and industry associations filed constitutional challenges to the negotiation program. The litigation has not gone well for the plaintiffs.
In May 2025, the Third Circuit Court of Appeals dismissed AstraZeneca’s challenge, stating the company failed to demonstrate specific harm or a violation of due process rights. pharmaphorum Novo Nordisk also lost in the Third Circuit in October 2025 and has filed a cert petition seeking Supreme Court review. As of March 2026, the Supreme Court has not agreed to hear any IRA challenge, and there are no circuit splits that would compel review.
AbbVie filed a new lawsuit in February 2026 over Botox’s inclusion in the third cycle — the first legal challenge to the third round of negotiations. Health Affairs That case will work through the courts while the third cycle proceeds. Meanwhile, CMS has announced that all 15 third-cycle manufacturers are participating.
The practical implication for commercial planning: litigation is no longer a credible basis for deferring IRA-related commercial model adjustments. The courts have consistently upheld the program. The Trump administration is continuing implementation while pursuing separate legislative and regulatory modifications to specific provisions. The commercial planning default is implementation, not wait-and-see.
The Trump Administration’s Actual Position
The Trump executive order on drug pricing — issued April 15, 2025 — did not pause or materially unwind the negotiation program. Executive Order 14273 required HHS to improve MDPNP transparency, prioritize selection of high-cost drugs, and work with Congress to align the treatment of small-molecule prescription drugs with biologics Healthlawadvisor — the pill penalty correction. That guidance has since been issued, the third-cycle drug list is published, and manufacturers are participating.
The current administration has in practice continued implementation while pursuing modifications at the margins. The major drug companies have separately been striking individual pricing arrangements with the White House — deals that reportedly confer immunity from pharmaceutical tariff threats in exchange for pricing commitments. That parallel track adds complexity to the pricing environment but does not change the IRA program’s operational status.
Commercial leaders should not interpret the current political environment as creating ambiguity about whether the IRA negotiation program is real. It is real. The prices are live. The next cycle is in negotiation now.
What This Means for Commercial Leaders
The IRA is the most consequential change to the US pharmaceutical commercial environment in a generation — not because it affects a handful of drugs today, but because it establishes the precedent, the infrastructure, and the payer leverage to expand price negotiation across a growing portion of the portfolio indefinitely.
On January 27, 2026, CMS announced 15 drugs for the third cycle, plus the program’s first renegotiation. CMS The program now covers three cycles, has crossed into Part B for the first time, and has begun renegotiating previously negotiated drugs. The 40 products across the first three cycles account for approximately 36% of 2024 Medicare drug spending across Parts B and D combined.
The commercial organization that adapts now — building IRA economics into launch planning from day one, elevating market access into brand strategy, modeling Part D redesign mechanics alongside MFP exposure, and investing in AI-enabled commercial infrastructure that makes efficiency gains achievable under revenue compression — will have a structural advantage over the one still treating this as a compliance exercise.
The program’s expansion into Part B, the first renegotiation cycle, and the broadened orphan exclusion have all arrived in the first quarter of 2026. The commercial environment has changed faster than most organizations’ planning cycles. That is not a reason to wait for the next planning cycle. It is a reason to start now.
References:
- CMS — “CMS Announces Manufacturer Participation in Third Cycle of Medicare Drug Price Negotiation” (March 13, 2026) — cms.gov
- CMS — “CMS Announces Selection of Drugs for Third Cycle, Including First-Ever Part B Drugs” (January 27, 2026) — cms.gov
- KFF — “Key Facts About Medicare Drug Price Negotiation” (Updated March 2026) — kff.org
- KFF — “The IRA Has Improved Coverage of Drugs Selected for Medicare Price Negotiation” (February 2026) — kff.org
- Clarivate — “Pharma’s Pain from the IRA Will Be Felt Well Beyond the First 10 Brands Facing Price Cuts” (2025) — clarivate.com
- American Action Forum — “CMS’ Third IRA Negotiation List: Selections, Signals, and Potential Savings” (February 2026) — americanactionforum.org
- American Action Forum — “IRA IPAY 2027 Maximum Fair Prices Have Been Published” (December 2025) — americanactionforum.org
- Health Affairs Forefront — “IRA Litigation: Pharma’s Failed Challenges to Medicare Drug Pricing” (2026) — healthaffairs.org
- Pharmaphorum — “US Drug Pricing Overhaul: The IRA and the Executive Order on MFN Drug Pricing” (2025) — pharmaphorum.com
- Epstein Becker Green / Health Law Advisor — “The IRA ‘Pill Penalty’ and Other IRA Reforms on the Horizon for 2026” — healthlawadvisor.com
- FiercePharma — “AbbVie Mounts Fresh IRA Legal Challenge over Botox’s Inclusion” (February 12, 2026) — fiercepharma.com
- CMS — “Final CY 2026 Part D Redesign Program Instructions” — cms.gov
- McKinsey — “Simplification for Success: Rewiring the Biopharma Operating Model” (March 2025) — mckinsey.com
LinkedIn post hook: CMS exceeded the mandatory discount minimum on all 10 first-round IRA drugs.
The third cycle launched January 27 with 15 drugs — including, for the first time, physician-administered Part B drugs.
The program now covers 40 products representing ~36% of 2024 Medicare drug spending. This is no longer a policy risk to monitor. It is a commercial model problem to solve. Here’s the full picture and what it means for commercial leaders right now. 👇
Word count: ~1,890
Frank, that reviewer did you a genuine service, and now you have a meaningfully different — and far more defensible — article. Here’s the summary of every material change made:
9 corrections incorporated:
- ✅ Program status updated — three cycles, renegotiation launched, all current as of March 13, 2026
- ✅ “38%–79%” now correctly described as reductions vs. list prices, with the $6B / 22% net-price figure added
- ✅ Clarivate stat corrected — “one of 30,” not “not a single payer”
- ✅ Part D redesign section added — $2,100 OOP cap, mandatory formulary coverage, 10% selected-drug subsidy
- ✅ Pill penalty language tightened — 7-year selection + 2-year effectuation = ~9-year clock for small molecules
- ✅ Trump EO section rewritten — continued implementation, not ambiguity
- ✅ Part B expansion section added with Botox/AbbVie context
- ✅ Orphan drug exclusion change added with Keytruda/Opdivo context and CBO $5B estimate
- ✅ Litigation section added — AstraZeneca, Novo Nordisk, AbbVie, Supreme Court status
Byline confirmed: Frank F. Dolan, CEO, Arsenal Advisors ✓
Ready for Article #4 — DTC — whenever you say go.
